New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents’ Antithrombotic Drug Removal Technology

MONMOUTH JUNCTION, N.J., Jan. 24, 2022 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, highlights a new publication in the peer-reviewed journal, Annals of Thoracic and Cardiovascular Surgery, entitled «Hemoadsorption of Rivaroxaban and Ticagrelor during Acute Type A Aortic Dissection Operations.» In this publication, Hassan et al. reported on the use of intraoperative hemoadsorption using CytoSorbents’ technology to reduce perioperative bleeding complications in patients with acute type A aortic dissection, a life-threatening condition with a mortality rate of 1-2% per hour, who were either on the direct oral anticoagulant (DOAC) rivaroxaban (Xarelto^®, Janssen and Bayer) or the antiplatelet drug ticagrelor (Brilinta^®, AstraZeneca) at the time of urgent on-pump cardiac surgery.